Appropriate use of cervical cancer vaccine

Annual Review of Medicine

Volumn 59, Issue , 2008, Pages 223-236

  Zimet, Gregory D ^a   Shew, Marcia L ^a   Kahn, Jessica A ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Adolescent; HPV; Human papillomavirus; Immunization; Vaccination

Indexed keywords

WART VIRUS VACCINE;

CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; NONHUMAN; PATIENT ATTITUDE; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

COST-BENEFIT ANALYSIS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PAPILLOMAVIRUS VACCINES; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 39649100449     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.59.092806.131644     Document Type: Review

References (77)

1. Bryan JT. 2007. Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine 25:3001-6
2. Winer RL, Lee S-K, Hughes JP, et al. 2003. Genital human papillomavirus: infection incidence and risk factors in a cohort of female university students. Am. J. Epidemiol. 157:218-26
3. Tarkowski TA, Koumans EH, Sawyer M, et al. 2004. Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. J. Infect. Dis. 189:46-50
4. Kahn JA, Lan D, Kahn RS. 2007. Sociodemographic factors associated with high-risk HPV infection in a national sample of U.S. women. Obstet. Gynecol. 110:87-95
5. Giuliano AR, Harris R, Sedjo RL, et al. 2002. Incidence, prevalence, and clearance of type specific human papillomavirus infections: the Young Women's Health Study. J. Infect. Dis. 186:462-69
6. Dunne EF, Unger ER, Sternberg M, et al. 2007. Prevalence of HPV infection among females in the United States. JAMA 297:813-19
7. Brown DR, Shew ML, Qadadri B, et al. 2005. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J. Infect. Dis. 191:182-92
8. Bosch FX, Lorincz A, Munoz N, et al. 2002. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55:244-65
9. Greer CE, Wheeler CM, Ladner MB, et al. 1995. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin. Microbiol. 33:2058-63
10. Moscicki A-B, Schiffman M, Kjaer S, et al. 2006. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine 24(Suppl. 3):42-51
11. Munoz N, Castellsague X, de Gonzalez AB, et al. 2006. Chapter 1: HPV in the etiology of human cancer. Vaccine 24(Suppl. 3):1-10
12. Parkin DM, Bray F, Ferlay J, et al. 2005. Global cancer statistics, 2002. CA Cancer J. Clin. 55:74-108
13. Jemal A, Siegel R, Ward E, et al. 2007. Cancer statistics, 2007. CA Cancer J. Clin. 57:43-66
14. Chesson HW, Blandford JM, Gift TL, et al. 2004. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect. Sex. Reprod. Health 36:11-19
15. Villa LL, Costa RL, Petta CA, et al. 2005. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6:271-78
16. Harper DM, Franco EL, Wheeler C, et al. 2004. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757-65
17. Harper DM, Franco EL, Wheeler CM, et al. 2006. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367:1247-55
18. Villa LL, Costa RLR, Petta CA, et al. 2006. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer 95:1450-66
19. Koutsky LA, Harper DM. 2006. Chapter 13: Current findings from prophylactic HPV vaccine trials. Vaccine 24(Suppl. 3):114-21
20. Centers for Disease Control and Prevention. 2007. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 56(No. RR-2):1-26
21. FUTURE II Study Group. 2007. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356:1915-27
22. Garland SM, Hernandez-Avila M, Wheeler CM, et al. 2007. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 356:1928-43
23. Block SL, Nolan T, Sattler C, et al. 2006. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (Types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 118:2135-45
24. Fraser C, Tomassini JE, Xi L, et al. 2007. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 25:4324-33
25. Olsson S-E, Villa LL, Costa RLR, et al. 2007. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25:4931-39
26. Ballout A, Goffin E, Yombi JC, et al. 2005. Vaccinations for adult solid organ transplant recipient: current recommendations. Transplant. Proc. 37:2826-27
27. Laurence JC. 2005. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am. J. Med. 118(10A):75S-83S
28. Viscidi RP, Snyder B, Cu-Uvin S, et al. 2005. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol. Biomarkers Prev. 14:283-88
29. Silverberg MJ, Schneider MF, Silver B, et al. 2006. Serological detection of human papillomavirus type 16 infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. Clin. Vaccine Immunol. 13:511-19
30. Kulasingam SL, Myers ER. 2003. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290:781-89
31. Goldie SJ, Kohli M, Grima D, et al. 2004. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl. Cancer Inst. 96:604-15
32. Taira AV, Neukermans CP, Sanders GD. 2004. Evaluating human papillomavirus vaccination programs. Emerg. Infect. Dis. 10:1915-23
33. Elbasha EH, Dasbach EJ, Insinga RP. 2007. Model for assessing human papillomavirus vaccination strategies. Emerg. Infect. Dis. 13:28-41
34. Garnett GP, Kim JJ, French K, et al. 2006. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 24(Suppl. 3):178-86
35. Sanders GD, Taira AV. 2003. Cost effectiveness of a potential vaccine for human papillomavirus. Emerg. Infect. Dis. 9:37-48
36. Zimet GD, Liddon N, Rosenthal SL, et al. 2006. Chapter 24: Psychosocial aspects of vaccine acceptability. Vaccine 24(Suppl. 3):201-9
37. Holcomb B, Bailey JM, Crawford K, et al. 2004. Adults' knowledge and behaviors related to human papillomavirus infection. J. Am. Board Fam. Pract. 17:26-31
38. Anhang R, Wright TC Jr, Smock L, et al. 2004. Women's desired information about human papillomavirus. Cancer 100:315-20
39. Noakes K, Yarwood J, Salisbury D. 2006. Parental response to the introduction of a vaccine against human papilloma virus. Hum. Vaccin. 2:243-48
40. Constantine NA, Jerman P. 2007. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J. Adolesc. Health 40:108-15
41. Brabin L, Roberts SA, Kitchener HC. 2007. A semiqualitative study of attitudes to vaccinating adolescents against human papillomavirus without parental consent. BMC Pub. Health 7:20
42. Lenselink CH, Gerrits MMJG, Melchers WJG, et al. 2008. Parental acceptance of human papillomavirus vaccines. Eur. J. Obstet. Gynecol. Reprod. Biol. In press
43. Woodhall SC, Lehtinen M, Verho T, et al. 2007. Anticipated acceptance of HPV vaccination at the baseline of implementation: a survey of parental and adolescent knowledge and attitudes in Finland. J. Adolesc. Health 40:466-69
44. Dinh TA, Rosenthal SL, Doan ED, et al. 2007. Attitudes of mothers in Da Nang, Vietnam toward a human papillomavirus vaccine. J. Adolesc. Health 40:559-63
45. Kahn JA, Zimet GD, Bernstein DI, et al. 2005. Pediatricians' intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J. Adolesc. Health 37:502-10
46. Riedesel JM, Rosenthal SL, Zimet GD, et al. 2005. Attitudes about human papillomavirus vaccine among family physicians. J. Pediatr. Adolesc. Gynecol. 18:391-98
47. Jain N, Irwin KL, Montano D, et al. 2006. Family physicians' knowledge of genital human papillomavirus (HPV) infection and HPV-related conditions, United States, 2004. Fam. Med. 38:483-89
48. Daley MF, Liddon N, Crane LA, et al. 2006. A national survey of pediatrician knowledge and attitudes regarding human papillomavirus vaccination. Pediatrics 118:2280-89
49. Tissot AM, Zimet GD, Rosenthal SL, et al. 2007. Effective strategies for HPV vaccine delivery: the views of pediatricians. J. Adolesc. Health 41:119-25
50. Mays RM, Zimet GD. 2004. Recommending STI vaccination to parents of adolescents: the attitudes of nurse practitioners. Sex. Trans. Dis. 31:428-32
51. Raley JC, Followwill KA, Zimet GD, et al. 2004. Gynecologists' attitudes regarding human papilloma virus vaccination: a survey of fellows of the American College of Obstetricians and Gynecologists. Infect. Dis. Obstet. Gynocol. 12:127-33
52. Silverman E. 2005. Cancer vaccine will be a hard sell. Newark Star Ledger, Apr. 3, Business Sec., p. 1
53. Liddon N. 2006. Record of the meeting of the Advisory Committee on Immunization Practices: behavioral issues related to HPV vaccination. http://www.cdc.gov/nip/ACIP/minutes/acip_min_feb06.pdf
54. Lo B. 2006. HPV vaccine and adolescents' sexual activity. BMJ 332:1106-7
55. Haber G, Malow RM, Zimet GD. 2007. The HPV vaccine mandate controversy. J. Pediatr. Adolesc. Gynecol. In press
56. Wilde GJS. 1998. Risk homeostasis theory: an overview. Inj. Prev. 4:89-91
57. O'Neill B, Williams A. 1998. Risk homeostasis hypothesis: a rebuttal. Inj. Prev. 4:92-93
58. Kirby D. 2002. The impact of schools and school programs upon adolescent sexual behavior. J. Sex Res. 39:27-33
59. Raine TR, Harper CC, Rocca CH, et al. 2005. Direct access to emergency contraception through pharmacies and effect on unintended pregnancy and STIs: a randomized controlled trial. JAMA 293:54-62
60. Pinkerton SD. 2001. Sexual risk compensation and HIV/STD transmission: empirical evidence and theoretical considerations. Risk Anal. 21:727-36
61. Van de Ven P, Mao L, Fogarty A, et al. 2005. Undetectable viral load is associated with sexual risk taking in HIV serodiscordant gay couples in Sydney. AIDS 19:179-84
62. Crepaz N, Hart TA, Marks G. 2004. Highly active antiretroviral therapy and sexual risk behavior. JAMA 292:224-36
63. Elford J. 2006. Changing patterns of sexual behaviour in the era of highly active antiretroviral therapy. Curr. Opin. Infect. Dis. 19:26-32
64. Elford J, Hart G. 2005. HAART, viral load and sexual risk behaviour. AIDS 19:205-7
65. Rubin R. 2005. Injected into a controversy. USA Today Oct. 19, p. 8D
66. Abma JC, Martinez GM, Mosher WD, et al. 2004. Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2002. Vital Health Stat. 23:1-87
67. Fortenberry JD, Costa FM, Jessor R, et al. 1997. Contraceptive behavior and adolescent lifestyles: a structural modeling approach. J. Res. Adolesc. 7:307-29
68. Agosti JM, Goldie SJ. 2007. Introducing HPV vaccine in developing countries - key challenges and issues. N. Engl. J. Med. 356:1908-10
69. Kane MA, Sherris J, Coursaget P, et al. 2006. Chapter 15: HPV vaccine use in the developing world. Vaccine 24(Suppl. 3):132-39
70. Stanton BF. 2004. Assessment of relevant cultural considerations is essential for the success of a vaccine. J. Health Popul. Nutr. 22:286-92
71. Streefland PH. 2003. Introduction of a HIV vaccine in developing countries: social and cultural dimensions. Vaccine 21:1304-9
72. Gauri V, Khaleghian P. 2002. Immunization in developing countries: its political and organizational determinants. World Dev. 30:2109-32
73. Middleman AB. 2007. Adolescent immunizations: policies to provide a shot in the arm for adolescents. J. Adolesc. Health 41:109-18
74. Charo RA. 2007. Politics, parents, and prophylaxis - mandating HPV vaccination in the United States. N. Engl. J. Med. 356:1905-8
75. Colgrove J. 2006. The ethics and politics of compulsory HPV vaccination. N. Engl. J. Med. 355:2389-91
76. Zimmerman RK. 2006. Ethical analysis of HPV vaccine policy options. Vaccine 24:4812-20
77. Gostin LO, DeAngelis CD. 2007. Mandatory HPV vaccination: public health vs private wealth. JAMA 297:1921-23